Paper Microfluidic Assay Patents: Leaders, Trends & White Space 2026
A data-driven look at paper microfluidic assay patents: who holds the largest filing positions, how filing activity has moved since 2017, which IPC classes carry the claim density, and where the white space sits for new
Filing growth = 2021 (16 records) → 2024 (12); 2024 is the last year we treat as complete. Top-5 share = the 5 largest assignees ÷ all 259 records in scope (CR5), not the ranked leaders only.
What the paper microfluidic assay filing record shows
Paper-based microfluidic assays sit at the intersection of low-cost point-of-care diagnostics and conventional lab testing, and the patent record reflects that split. 259 records published between 2015 and the 2026-08-31 cut-off cover everything from lateral-flow strip geometry to three-dimensional paper microchip structures for antigen detection. The claim language clusters heavily around material analysis and testing (G01N) rather than around the fluidic hardware itself, which tells you where the drafting effort in this field has actually gone.
Filing activity rose through the late 2010s, peaked in 2020, and has since pulled back — a pattern consistent with a technology that reached a first wave of claim staking around diagnostic testing formats before slowing. Because publication lags filing by roughly 18 months, the 2025 and 2026 figures in any trend line are undercounts, not evidence of a stalled field.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing concentration, trend and technology mix
Three views of the same 259-record dataset: who is filing, when they filed, and what part of the paper microfluidic stack their claims sit on.
Filing trend, 2017–2026
Filings rose from 17 in 2017 to a peak of 28 in 2020, then eased; the 2021-to-2024 window shows a 25% decline (16 to 12), and 2025–2026 are still filling in under the usual publication lag.
Publication lags filing by roughly 18 months, so 2025 onwards are still filling in. Growth rates on this page therefore end at 2024; running them to the last bar would understate the field.
Technology composition by IPC subclass
G01N (material analysis & testing) covers 68.3% of the 259 records, well ahead of B01L (lab apparatus, 30.9%) and C12Q (enzyme/DNA testing, 19.3%); records can carry more than one class, so shares do not sum to 100%.
Shares are the percentage of the 259 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Lab-on-a-Chip & Microfluidics: Paper Microfluidic Assay Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about lab-on-a-chip & microfluidics: paper microfluidic assay patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records and a representative claim
Paper-based three-dimensional structure microchip for detecting target antigen (US20210237060A1)
The filing describes a paper-based microfluidic device built from a pattern film, conjugate and absorption pads inserted into formed holes and held at a fixed interval, an aptamer-and-antibody reagent stored above the conjugate pad, a reaction pad carrying an antibody that binds the target antigen, and a cover film with a space formed beneath the reaction pad by film removal.Filed by Uniance Gene Co., Ltd, published 2021-08-05.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20100274155A1 | Sanitary swab collection system, microfluidic assay device, and methods for diagnostic assays | 128 |
| 2 | WO2009018473A1 | Sanitary swab collection system, microfluidic assay device, and methods for diagnostic assays | 105 |
| 3 | WO2009121037A2 | Three-dimensional microfluidic devices | 53 |
| 4 | US20120070833A1 | Lateral flow microfluidic assaying device and related method | 46 |
| 5 | WO2009121041A2 | Paper-based microfluidic systems | 39 |
| 6 | WO2013036617A1 | Microfluidic devices for multiplexed electrochemical detection | 37 |
| 7 | US20160016166A1 | Molecular diagnostic devices with magnetic components | 36 |
| 8 | US20140183059A1 | Microfluidic devices for multiplexed electrochemical detection | 35 |
| 9 | WO2014047285A1 | Identifying taxane sensitivity in prostate cancer patients | 34 |
| 10 | US20150233927A1 | Identifying taxane sensitivity in prostate cancer patients | 31 |
Citation counts favour older filings inside any searched corpus — read them as a signal of influence on later drafting, not as a ranking of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Reading the concentration and the technology split
The numbers point to a field with a recognisable leader group, a heavy skew toward test-and-measure claims, and a filing curve that has cooled since 2020 without disappearing.
A leader, then a long tail
The leading assignee holds 21 records, fifth place holds 11, and tenth place holds 7 — a steep drop-off inside the ranked leaders rather than a flat distribution. That shape means the largest single filer has a real position, but the next tier down thins out fast, leaving room for a determined new entrant to build a comparable-sized portfolio.
Testing claims dominate over hardware claims
G01N (material analysis and testing) appears on more than two-thirds of the 259 records, far ahead of B01L (lab apparatus, 30.9%) and C12Q (enzyme/DNA testing, 19.3%). That skew suggests the assay chemistry and readout methods are more densely claimed than the physical chip architecture itself.
Activity has eased from its 2020 peak
Filings rose from 17 in 2017 to 28 in 2020, then declined to 12 by 2024 — the last year in this dataset that can be treated as complete. The drop does not necessarily mean interest is fading; it may reflect that the most obvious assay-format claims were staked early in the cycle.
Filing is spread across multiple offices
The United States leads with 72 records, followed by WIPO PCT filings at 48 and the European Patent Office at 39; India, Australia and Canada each carry smaller but non-trivial counts. That spread indicates applicants are pursuing multi-jurisdiction protection rather than concentrating on a single home market.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to lab-on-a-chip & microfluidics: paper microfluidic assay patent landscape, with the prior art for and against each one.
Where to take this analysis
The filing data narrows down who to watch and which claim areas are already crowded; the next step is turning that into a freedom-to-operate or whitespace view for a specific design.
Map a specific assay design against the leader portfolios
Run a candidate lateral-flow or 3D paper-chip design against the largest filers' claim sets to see which elements are already covered and which are open.
Explore in Patsnap EurekaTrack the under-claimed IPC branches
B01D separation processes and A61K medicinal-preparation overlaps sit well below the G01N testing cluster — worth a closer look before assuming the space is taken.
Explore in Patsnap EurekaWatch the co-assignee clusters for partnership signals
The strongest co-filing pairs point to active research collaborations; tracking their newer filings can flag where a portfolio is about to expand.
Explore in Patsnap EurekaCommon questions on paper microfluidic assay patents
The dataset ranks 100 assignees by records, with the leading filer holding 21 of the 259 records in scope. The top five combined hold 27.8% of all records, and the top ten hold 42.1%, which means there is a clear leader group but not an overwhelming monopoly. Beyond the tenth position filing counts drop into single digits quickly, so most of the ranked leaders are one- or few-filing entrants rather than sustained portfolio builders.
Filing rose from 17 records in 2017 to a peak of 28 in 2020, then eased to 12 by 2024, a 25% decline over that three-year span. 2024 is the most recent year that can be treated as complete, because publication typically lags filing by around 18 months, so 2025 and 2026 figures in this dataset are still filling in. The honest read is that activity has cooled from its 2020 high rather than that it has stopped.
G01N, covering material analysis and testing, appears on 68.3% of the 259 records and is by far the dominant class. B01L (lab apparatus) follows at 30.9% and C12Q (enzyme and DNA-related testing) at 19.3%, with A61B diagnosis-and-surgery claims and C12M bioreactor claims appearing on smaller shares. Because a single record can carry several IPC classes, these shares add up to more than 100% and should not be summed or compared as if they were mutually exclusive categories.
The United States receives the most filings at 72 records, ahead of WIPO PCT applications at 48 and the European Patent Office at 39. India, Australia and Canada each carry smaller counts, but their presence shows applicants are pursuing coverage well beyond a single home market. This spread is typical of a diagnostics-adjacent technology where commercial deployment often targets multiple regulatory regions at once.
US20210237060A1 describes a paper-based three-dimensional microchip that uses a pattern film with a conjugate pad and absorption pad inserted into formed holes at a fixed interval, a reaction pad carrying an antibody bound to the target antigen, and a cover film creating a space beneath the reaction pad by film removal. Anyone designing a similar pad-and-film antigen-detection architecture should read the claims closely, since the specific pad placement and film-removal geometry are the elements most likely to matter for a freedom-to-operate check. It does not, on its own, cover every paper microfluidic assay format — lateral-flow and non-antigen assay chemistries described in other records sit outside its specific structure.
Research Lab-on-a-Chip & Microfluidics: Paper Microfluidic Assay Patent Landscape in depth with Eureka
Go past this page: query the whole lab-on-a-chip & microfluidics: paper microfluidic assay patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.